TY - JOUR
T1 - Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis
T2 - A Patient-Level Propensity-Matched Analysis
AU - Pediatric Emergency Research Canada and Pediatric Emergency Care Applies Research Networks
AU - Powell, Elizabeth C.
AU - Roskind, Cindy G.
AU - Schnadower, David
AU - Olsen, Cody S.
AU - Casper, T. Charles
AU - Tarr, Phillip I.
AU - O'Connell, Karen J.
AU - Levine, Adam C.
AU - Poonai, Naveen
AU - Schuh, Suzanne
AU - Rogers, Alexander J.
AU - Bhatt, Seema R.
AU - Gouin, Serge
AU - Mahajan, Prashant
AU - Vance, Cheryl
AU - Hurley, Katrina
AU - Farion, Ken J.
AU - Sapien, Robert E.
AU - Freedman, Stephen B.
N1 - Funding Information:
Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. The current subanalysis was unfunded. The data analyzed were from The Pediatric Emergency Care Applied Research Network (PECARN) Probiotic Study, funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and from the Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment (PROGUT) study, funded by the Canadian Institutes of Health Research. Dr. Freedman is supported by the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness. Dr. Stephen Freedman has served as a consultant to Redhill Biopharma and has received in kind study drug and placebo from GlaxoSmithKline and Institut Rosell Inc.
Funding Information:
Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org ). The authors have stated that no such relationships exist. The current subanalysis was unfunded. The data analyzed were from The Pediatric Emergency Care Applied Research Network (PECARN) Probiotic Study, funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and from the Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment (PROGUT) study, funded by the Canadian Institutes of Health Research. Dr. Freedman is supported by the Alberta Children’s Hospital Foundation Professorship in Child Health and Wellness. Dr. Stephen Freedman has served as a consultant to Redhill Biopharma and has received in kind study drug and placebo from GlaxoSmithKline and Institut Rosell Inc.
Publisher Copyright:
© 2021 American College of Emergency Physicians
PY - 2022/1
Y1 - 2022/1
N2 - Study objective: This study aimed to explore oral ondansetron usage and impact on outcomes in clinical practice. Methods: This observational study was a planned secondary analysis of 2 trials conducted in 10 US and 6 Canadian institutions between 2014 and 2017. Children 3 to 48 months old with gastroenteritis and ≥3 episodes of vomiting in the 24 hours preceding emergency department (ED) presentation were included. Oral ondansetron was administered at the discretion of the provider. The principal outcomes were intravenous fluid administration and hospitalization at the index visit and during the subsequent 72 hours and diarrhea and vomiting frequency during the 24 hours following the ED visit. Results: In total, 794 children were included. The median age was 16.0 months (interquartile range 10.0 to 26.0), and 50.1% (398/794) received oral ondansetron. In propensity-adjusted analysis (n=528), children administered oral ondansetron were less likely to receive intravenous fluids at the index visit (adjusted odds ratio [aOR] 0.50; 95% confidence interval [CI] 0.29 to 0.88). There were no differences in the frequencies of intravenous fluid administration within the first 72 hours (aOR 0.65; 95% CI 0.39 to 1.10) or hospitalization at the index visit (aOR 0.31; 95% CI 0.09 to 1.10) or the subsequent 72 hours (aOR 0.52; 95% CI 0.21 to 1.28). Episodes of vomiting (aRR 0.86; 95% CI 0.63 to 1.19) and diarrhea (aRR 1.11; 95% CI 0.93 to 1.32) during the 24 hours following ED discharge also did not differ. Conclusion: Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge.
AB - Study objective: This study aimed to explore oral ondansetron usage and impact on outcomes in clinical practice. Methods: This observational study was a planned secondary analysis of 2 trials conducted in 10 US and 6 Canadian institutions between 2014 and 2017. Children 3 to 48 months old with gastroenteritis and ≥3 episodes of vomiting in the 24 hours preceding emergency department (ED) presentation were included. Oral ondansetron was administered at the discretion of the provider. The principal outcomes were intravenous fluid administration and hospitalization at the index visit and during the subsequent 72 hours and diarrhea and vomiting frequency during the 24 hours following the ED visit. Results: In total, 794 children were included. The median age was 16.0 months (interquartile range 10.0 to 26.0), and 50.1% (398/794) received oral ondansetron. In propensity-adjusted analysis (n=528), children administered oral ondansetron were less likely to receive intravenous fluids at the index visit (adjusted odds ratio [aOR] 0.50; 95% confidence interval [CI] 0.29 to 0.88). There were no differences in the frequencies of intravenous fluid administration within the first 72 hours (aOR 0.65; 95% CI 0.39 to 1.10) or hospitalization at the index visit (aOR 0.31; 95% CI 0.09 to 1.10) or the subsequent 72 hours (aOR 0.52; 95% CI 0.21 to 1.28). Episodes of vomiting (aRR 0.86; 95% CI 0.63 to 1.19) and diarrhea (aRR 1.11; 95% CI 0.93 to 1.32) during the 24 hours following ED discharge also did not differ. Conclusion: Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge.
UR - http://www.scopus.com/inward/record.url?scp=85112510790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112510790&partnerID=8YFLogxK
U2 - 10.1016/j.annemergmed.2021.06.003
DO - 10.1016/j.annemergmed.2021.06.003
M3 - Article
C2 - 34389195
AN - SCOPUS:85112510790
VL - 79
SP - 66
EP - 74
JO - Journal of the American College of Emergency Physicians
JF - Journal of the American College of Emergency Physicians
SN - 0196-0644
IS - 1
ER -